

HORIZONS-AMI Trial 12-Month Outcomes

OBJECTIVE:	Evaluate the safety and efficacy of the TAXUS® Express® Stent compared to Express® bare metal stent in patients with acute ST-elevation MI
STENT:	TAXUS Express Stent
PURPOSE:	Safety and efficacy of a drug eluting stent in AMI patients
DESIGN:	Prospective, randomized 3:1 (TAXUS Express Stent to Express Bare Metal Stent)
LESION:	At least one acute infarct artery target vessel with a reference vessel diameter ≥ 2.25 and ≤ 4.0 mm
CONTROL:	Express Bare Metal Stent
PRIMARY EFFICACY ENDPOINT:	12-month ischemic target lesion revascularization (Efficacy test for superiority in ischemic TLR)
PRIMARY SAFETY ENDPOINT:	12-month safety composite (all cause death, reinfarction, stent thrombosis (ARC definite or probable) or stroke (Composite Safety MACE test for non-inferiority))
LOCATION & SITES:	Global (11 countries) and 123 centers
PATIENTS:	3,062 STEMI Patients / 3,006 patients randomized to stents
PRESENTERS:	Gregg W. Stone, MD

Patient Characteristics	TAXUS® Express® Stent (N=2,257)	Express® Bare Metal Stent (N=749)	p-Value
Age, mean \pm SD (years)	59.9	59.3	NS
Male	77.0%	76.0%	NS
Diabetes	16.1%	15.2%	NS
Hypertension	51.2%	51.9%	NS
Hyperlipidemia	42.2%	41.1%	NS
Current Smoker	46.3%	51.9%	0.009
Prior MI	9.1%	10.9%	NS
Prior PCI	9.5%	7.7%	NS
Prior CABG	2.2%	1.9%	NS
Weight (kg)	80	80	NS
Killip class 2-4	8.8%	8.0%	NS
Anterior MI	42.2%	44.7%	NS
LVEF (%), site	50	50	NS
Symptoms – PCI, hrs	3.7	3.8	NS
Femoral a. access	93.6%	92.9%	NS
Venous access	8.5%	8.0%	NS
Closure device	30.1%	28.8%	NS
Aspiration catheter	11.4%	10.7%	NS

Procedural Data (Site Reported)	TAXUS® Express® Stent (N=2,257 / L=2,495)	Express ² ® Bare Metal Stent (N=749 / L=815)	p-Value
N lesions treated	1.1 \pm 0.4	1.1 \pm 0.4	NS
≥ 2 lesions treated	11.1%	9.0%	NS
≥ 2 vessels treated	4.5%	3.1%	NS
Direct stenting attempted	30.4%	33.7%	NS
Stent target lesion: (%) LAD, LCX, RCA, LM, SVG	40.1 / 14.6 / 45.1 / 0.3 / 0.3	42.4 / 15.9 / 41.3 / 0.4 / 0.4	NS
N stents implanted	1.5 \pm 0.9	1.4 \pm 0.7	0.002
Total stent length	30.8 \pm 17.8	27.3 \pm 14.9	<0.0001
Max balloon dia (mm)	3.00	3.00	NS
Max pressure (atm.)	14.0	14.0	NS

12-month Clinical Event Rates*	TAXUS® Express® Stent (N=2,257)	Express ² ® Bare Metal Stent (N=749)	p-Value
MACE	8.1%	8.0%	0.92
Ischemic TLR	4.5%	7.5%	0.002
Ischemic TVR	5.8%	8.7%	0.006
MI	3.7%	4.5%	0.31
All Cause Mortality	3.5%	3.5%	0.98
Stent Thrombosis (ARC Def or Probable)	3.1%	3.4%	0.72

*Kaplan-Meier Rates



Boston Scientific Corporation
One Boston Scientific Place
Natick, MA 01760-1537
www.bostonscientific.com

© 2008 Boston Scientific Corporation or its affiliates. All rights reserved.
USPG 5801.107.0 Oct 2008